Clinical Trial Detail

NCT ID NCT02963831
Title A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Ludwig Institute for Cancer Research
Indications

fallopian tube cancer

cervical cancer

esophageal cancer

endometrial cancer

endometrial stromal sarcoma

gastrointestinal neuroendocrine tumor

ovary epithelial cancer

colorectal cancer

uterus leiomyosarcoma

stomach cancer

vulva cancer

peritoneum cancer

uterine carcinosarcoma

pancreatic cancer

malignant mesothelioma

cholangiocarcinoma

vaginal cancer

Therapies

Durvalumab + ONCOS-102

Age Groups: senior adult

No variant requirements are available.